Alison Schram
@AliSchram
Followers
859
Following
615
Statuses
80
Medical Oncologist, Early Drug Development and Gynecologic Malignancies, Memorial Sloan Kettering Cancer Center.
New York, USA
Joined December 2015
RT @IASLC: #ICYMI, the FDA recently approved zenocutuzumab for NSCLC with an NRG1 fusion! Catch this all-new episode of #LungCancerConsider…
0
7
0
I am commonly asked what the benchmarks are for a target-drug pair to have tumor-agnostic potential. See the new ETAC-S! @Annals_Oncology @myESMO @VivekSubbiah @JulianaRBeal @curijoey @Dr_R_Kurzrock @SewantiLimaye @StefanMichiels @quimmateo @niamhjcoleman @FAndreMD @ElenaGarralda
ESMO announces the publication of the ESMO Tumour-Agnostic Classifier and Screener (ETAC-S), a new framework to assess the tumour-agnostic potential of #CancerTherapies with the aim to optimise the drug development process @Annals_Oncology. 🔗
1
9
26
I second this. Pat you are a powerhouse, role model, mentor, brilliant trialist and compassionate doctor. AACR is in the best hands. Congrats! @AACRPres
One of the kindest, smartest and generous humans I know! Congrats Pat!!!
0
0
5
Fun session thanks to @VivekSubbiah, Christophe Le Tourneau, and Jordi Rodon complete with a sonnet about tumor agnostic drug development by ChatGPT/Vivek! 🎯🧬💊😂
⭐️@AliSchram @MSKCancerCenter just after a phenomenal presentation of the tumor agnostic data from the lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor in FGFR2-altered tumors. Dr. Schram nailed it at the Q &A session. 👉🏼So amazing to watch the @Relay_Tx drug go from bench to first in human to a tissue agnostic #PrecisionMedicine drug.
0
2
26
RT @VivekSubbiah: ⭐️Mark your calendars if you are attending the triple meeting 👉 Super thrilled to be discussing about the "Future of Tiss…
0
13
0
Well deserved! @TinaJost4 I hope you continue this great work on the mechanism of radiosensitization and most effective use of DDR therapies
Thanks to @AliSchram and #esmotat23 for the best poster price on kinase-targeting agents and cell signalling modulators. #dnarepair #kinaseinhibitors #targetedtherapy
0
0
3
RT @NeilVasan: We are pleased to announce our manuscript on pan-cancer multi-PIK3CA mutations, published this week in @CCR_AACR. https://t…
0
26
0
@rosslevinemd @RossLevineLab @cohesinlab @bowman_rl @lindemilesphd @gur_ola @shengfcai @JAK2TheFuture Love this! @PedsHemeDoc We’re definitely OG. I remember meeting with @rosslevinemd at ZRC to interview for the lab before @RossLevineLab had any lab space 😁, although it was entirely clear after that convo he would be this successful.
0
0
2
RT @VivekSubbiah: 🎯On behalf of all co-investigators presenting👉Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma using a nove…
0
23
0
@DrSapnaPatel @MyriamChalabi @BenWestphalen @JenSeligmann @FilippoPietran4 WWeawswAT3333 we are s we s we sa m
0
0
0
In case you missed it, updated results from the eNRGy study presented at #ASCO22! Zeno ORR of 34% (27/79) across tumor types & 42% (8/19) in PDAC. Median DOR of 9.1 mo and extremely well tolerated. Zeno has the potential to become new SOC for this unmet clinical need.
2
42
128
@DrEzraRosen @alexdrilon @DrBetofMDPhD @HaradaGuilherme @YoninaMG @dazhiliurx @RobinGuo5 @MSKCancerCenter Love this team!!! Sorry to have missed this.
0
0
1
Grateful to be involved in this exciting study demonstrating efficacy targeting the elusive p53 (Y220C). Cool biology and helping patients!
Looking forward to this #ASCO22 presentation by @cathy_ileana_md on a first-in-class mutant p53 structural corrector
0
1
8
RT @MSKCancerCenter: Despite having lost her voice, @HillaSolomon told us all about her group's research on possible #EndometrialCancer tre…
0
4
0
Thrilled to share MSKs preclinical and initial clinical experience with Zeno which led to the ongoing eNRGy study. Treating these pts has been a highlight of my career. Grateful to have incredible lab collaborators and be at @sloan_kettering where anything is possible.
Now online in @CD_AACR: Zenocutuzumab, a #HER2 x #HER3 #bispecific antibody, is effective therapy for tumors driven by #NRG1 gene rearrangements - by @AliSchram @odintosov_I Romel Somwar and colleagues @sloan_kettering
6
4
63